酪氨酸激酶抑制剂治疗慢性髓性白血病的预后系统及因素的比较分析(2)
Results 72 patients were enrolled(39 males and 33 females)，and the median age was 45(10-81) years.Up to December 31，2019，the median observation period was 61(4-96) months，8 patients died，and the median 5-year OS rate was 88.89% after imatinib treatment.42 patients had disease progression，with a median 5-year PFS rate of 41.67%.The OS rate of each group showed that Euro integral system was(96.97% VS 87.50%VS 51.14%)，EUTOS integral system was (96.23% VS 31.58%)，6 months EMR was (100.00% VS 83.33% VS 76.47%)，and the difference of OS rate of each group was statistically significant，P values were 0.003，0.001 and 0.039，respectively.Sokal integral system was (90.00% VS 94.87% VS 78.26%) and 3 months EMR (92.00% VS 81.82%)，and the difference of median 5-year OS in each group was not statistically significant，P values were 0.107 and 0.120，respectively.Sokal integral system was (70.00% VS 41.03% VS 26.09%)，Euro integral system was (51.52% VS 40.63% VS 0.00%)，EUTOS integral system was (49.06% VS 21.05%)，EMR of 3 months was (54.00% VS 13.64%)，EMR of 6 months was (74.07% VS 20.83% VS 5.88%)，and the difference of median 5-year PFS in each group was statistically significant，P values were 0.002，<0.001，<0.016，<0.001 and <0.001，respectively.
Conclusion The Euro score，EUTOS score and 6 months EMR can predict the OS in the patients with CML-CP treated with TKI，and Sokal score，Euro score and EUTOS score，3 months EMR and 6 months EMR can predict PFS., 百拇医药(张淳嘉 郑小玲 郑丹钿 夏维林 苏秀连)
Conclusion The Euro score，EUTOS score and 6 months EMR can predict the OS in the patients with CML-CP treated with TKI，and Sokal score，Euro score and EUTOS score，3 months EMR and 6 months EMR can predict PFS., 百拇医药(张淳嘉 郑小玲 郑丹钿 夏维林 苏秀连)